1 Top Healthcare Stock to Buy Low Today

Cardiol Therapeutics Inc. (TSX:CRDL) is an exciting healthcare stock that aims to make strides in the application of CBD going forward.

Cardiol Therapeutics (TSX: CRDL) is an Oakville-based clinical-stage biotechnology company that is focused on the research and development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). In late 2021, I’d looked at some of the top healthcare stocks that were worth snatching up before the new year. Today, I want to discuss whether Cardiol is worth buying as we prepare to move into the month of February.

This healthcare stock has gained momentum in 2022

Shares of Cardiol Therapeutics have climbed 6.3% week over week as of early afternoon trading on January 31. The stock is up 1.2% so far this year. However, Cardiol stock is still down 25% in the year-over-year period.

Health care is already one of the most explosive sectors that investors can target right now. However, biotechnology is its fastest-growing subsector. In 2021, Grand View Research estimated that the global biotechnology market was valued at US$752 billion in 2020. The market researcher projects that this market will deliver a CAGR of 15% from 2021 through 2028. This should spur investors to get in on this healthcare stock as January comes to an end.

How has this company performed recently?

Investors can expect to see this company’s fourth-quarter and full-year 2021 results in late March. It released its third-quarter 2021 earnings on November 15. Cardiol’s lead product — CardiolRx — is an oral cannabidiol formulation. Cardiol’s total current assets have climbed to $30.9 million at the end of Q3 2021 — up from $14.9 million as of September 31, 2020.

The FDA recently gave Cardiol clearance to move forward with its Phase II multi-centre, randomized controlled trial of CardiolRx among 100 patients with acute myocarditis (AM). This trial will include patients in Europe and the United States.

Acute myocarditis does not have a widely effective and uniform treatment. Cardiol’s leadership has hailed the anti-inflammatory and cardioprotective properties of CBD in models of cardiovascular disease. Of course, this research is still in its very early stages. The utility of CBD as a legitimate medicine is a matter of some debate. Cardiol’s ongoing trials may provide some much-needed clarity on this point.

Myocarditis is a disease that affects roughly 200,000 people in the United States and Canada. The development of a proven new therapy would put Cardiol in a terrific position to fill the void for treatment in the year ahead.

Should you buy Cardiol stock today?

Cardiol is on pace for strong revenue growth going forward. This should spur investors to take a hard look at this healthcare stock as we move into February. Moreover, it boats an excellent balance sheet.

This company is projecting multi-million-dollar revenues by 2022. Shares of this healthcare stock are trading in favourable value territory compared to its industry peers. Investors should remember that this clinical-stage company offers significant risk. That said, it has nice potential, as it seeks to make a breakthrough treating a disease that thus far has puzzled the medical community. Moreover, it will provide a big test for the viability of CBD in this sphere.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Investing

container trucks and cargo planes are part of global logistics system
Dividend Stocks

How Much Would You Need in Exchange Income to Collect $100 a Month?

Exchange Income pays monthly. At its recent price, getting $100 a month from it alone would take just over $51,000.…

Read more »

woman considering the future
Energy Stocks

Should You Buy Enbridge Stock Today for Its 5.7% Dividend Yield?

Discover the factors affecting Enbridge’s stock as it faces challenges with acquisitions and increased capital spending.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

Why I Love VDY and Its Generous 3% Dividend Yield

This popular Canadian dividend ETF pays a decent monthly yield, charges low fees, and has historically beat the market.

Read more »

TFSA (Tax free savings account) acronym on wooden cubes on the background of stacks of coins
Energy Stocks

How I’d Build $57 a Month in Tax-Free TFSA Income With Northland and Peyto

Northland and Peyto are benefitting from strong sector fundamentals, resulting in rising cash flows, and possibly more dividend hikes.

Read more »

Investor wonders if it's safe to buy stocks now
Dividend Stocks

Enbridge Stock: Is It Still a Top Passive Income Pick for Retirees?

Enbridge's attractive 5.7% dividend yield, improving cash flows, and massive growth backlog make it a compelling passive income stock for…

Read more »

earn passive income by investing in dividend paying stocks
Dividend Stocks

$10,000 in Your TFSA: 2 Stocks to Buy for Passive Income

Given their well-established businesses, reliable cash flows, consistent dividend payouts, and high yields, these two Canadian stocks are ideal for…

Read more »

Colored pins on calendar showing a month
Dividend Stocks

What $40,000 in a Dividend Portfolio Could Pay Without Selling Shares

A $40,000 portfolio can help with recurring bills even if you leave every share in the account. Here’s what three…

Read more »

tsx today
Stock Market

TSX Today: Why the Canadian Stock Market Sell-off Could Intensify on Wednesday, November 18

The TSX could extend its losing streak at the open today as gold and silver prices tumble to their lowest…

Read more »